UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (17) 17
humans (16) 16
life sciences & biomedicine (16) 16
female (12) 12
male (12) 12
oncology (11) 11
adult (10) 10
hematology, oncology and palliative medicine (10) 10
lung cancer (10) 10
middle aged (10) 10
carcinoma, non-small-cell lung - drug therapy (9) 9
lung cancer, non-small cell (9) 9
lung neoplasms - drug therapy (9) 9
lung neoplasms - pathology (9) 9
mutation (9) 9
aged (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
care and treatment (8) 8
chemotherapy (8) 8
cancer (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
lung neoplasms - genetics (7) 7
lung neoplasms - mortality (7) 7
neoplasm staging (7) 7
aged, 80 and over (6) 6
cancer therapies (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
disease-free survival (6) 6
medical colleges (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
quinazolines - administration & dosage (5) 5
receptor, epidermal growth factor - genetics (5) 5
treatment outcome (5) 5
tumors (5) 5
clinical trials (4) 4
kaplan-meier estimate (4) 4
pharmaceutical industry (4) 4
protein kinase inhibitors - administration & dosage (4) 4
receptor, epidermal growth factor - antagonists & inhibitors (4) 4
analysis (3) 3
cisplatin - administration & dosage (3) 3
drug administration schedule (3) 3
gefitinib (3) 3
general & internal medicine (3) 3
genetic predisposition to disease (3) 3
internal medicine (3) 3
lymphoma (3) 3
medicine, general & internal (3) 3
metastasis (3) 3
ovarian cancer (3) 3
product development (3) 3
studies (3) 3
abridged index medicus (2) 2
administration, oral (2) 2
age (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
asia (2) 2
biological and medical sciences (2) 2
carcinoma, non-small-cell lung - enzymology (2) 2
children (2) 2
complications and side effects (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease progression (2) 2
docetaxel (2) 2
double-blind method (2) 2
drug therapy (2) 2
erlotinib hydrochloride (2) 2
follow-up studies (2) 2
gene expression (2) 2
gene expression regulation, neoplastic (2) 2
genetic aspects (2) 2
glutamates - administration & dosage (2) 2
guanine - administration & dosage (2) 2
guanine - analogs & derivatives (2) 2
health aspects (2) 2
kinases (2) 2
lung neoplasms - enzymology (2) 2
lung neoplasms - therapy (2) 2
medical oncology - standards (2) 2
medical sciences (2) 2
mutation - genetics (2) 2
patients (2) 2
pemetrexed (2) 2
phenotype (2) 2
prognosis (2) 2
proportional hazards models (2) 2
prospective studies (2) 2
proto-oncogene proteins - genetics (2) 2
quinazolines - adverse effects (2) 2
quinazolines - therapeutic use (2) 2
radiation therapy (2) 2
research (2) 2
risk factors (2) 2
strategic planning (2) 2
survival analysis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer | Index Medicus
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 709 - 719
Journal Article